INTRODUCTION
Mepolizumab has been shown to reduce exacerbations [1] [2] [3] [4] and oral corticosteroid use [5, 6] , as well as to improve quality of life [1, 3, 4, 6] and asthma control [3, 4, 6] . However, lung function results were inconsistent in early studies [1, 2, 7] . For example, nearly a decade ago, Flood-Page and colleagues reported that mepolizumab treatment failed to show meaningful changes in the primary endpoint of morning peak expiratory flow (AM PEF). However, these patients were not selected using criteria now known to be associated with a positive treatment response to mepolizumab [7] .
Our understanding of the severe eosinophilic asthma phenotype likely to respond to mepolizumab treatment was informed by a series of studies following the report by Flood-Page and colleagues which systematically refined the target population for mepolizumab treatment. In the proof of concept study by Haldar and colleagues [1] as well as the DREAM study [2] a significant reduction in exacerbations (approximately 50%) was demonstrated, whereas changes in lung function were modest. The lack of effect on lung function may have resulted from the non-specific approach in selecting study participants. For example, DREAM allowed four different biomarkers to identify the eosinophilic phenotype. However, of these, only the baseline blood eosinophil count combined with the frequency of prior exacerbations was predictive in a modelling analysis of positive treatment response to mepolizumab, measured by the magnitude of the relative reduction in exacerbations compared with placebo [2] . These findings formed the basis of the clinical characteristics and the blood eosinophil thresholds now used to select patients for treatment with mepolizumab. As such, the more recent studies, MENSA (NCT01691521) and MUSCA (NCT02281318), utilized these key predictor characteristics to select study participants: blood eosinophil count of at least 150 cells/lL at screening or 300 cells/lL in the past 12 months, plus at least two exacerbations in the past 12 months despite high dose inhaled corticosteroid (ICS) and another controller medication [3, 4] . These two studies also showed a reduction in exacerbations ranging from 52% to 58%, and demonstrated improvements in quality of life, asthma control, and FEV 1 [3, 4] .
Mepolizumab is an anti-interleukin (IL)-5 monoclonal antibody that is approved as an add-on therapy to standard of care for severe asthma in adolescents and adult patients with an eosinophilic phenotype [8, 9] . This report describes the result of the individual studies as well as a meta-analysis of AM PEF from studies using both the commercialized dose of mepolizumab 100 mg administered subcutaneously and the refined criteria which select patients likely to respond to mepolizumab treatment. In this post hoc analysis we also assess the onset of clinical effect and the relationship between baseline blood eosinophil count thresholds and lung function changes measured by AM PEF following treatment with mepolizumab.
METHODS

Included Studies
Criteria used for the inclusion of studies in the meta-analysis were placebo-controlled studies of mepolizumab 100 mg SC in severe eosinophilic asthma in patients with two or more exacerbations in the past year; studies utilizing a blood eosinophil threshold of at least 150 cells/lL at screening (or at least 300 cells/lL in the previous year) to select the target population; dose of baseline asthma medications kept constant throughout study; and duration of at least 24 weeks. Studies included on the basis of these criteria were the MENSA study (GSK/ ClinicalTrials.gov identifier MEA115588/ NCT01691521) and the MUSCA study (Study 200862/NCT02281318) [3, 4] . The protocol for the current analysis is available from the GSK Clinical Study Register (number 208091) [10] .
Patients
Enrollment criteria for the studies have been previously published [3, 4] . Briefly, patients were aged at least 12 years; required to have had a clinical diagnosis of asthma; had a history of at least two exacerbations requiring systemic corticosteroid treatment in the previous year, and disease severity consistent with the ERS/ATS definition for severe asthma [11, 12] . Eosinophilic inflammation was defined as a blood eosinophil count of at least 150 cells/lL at screening or at least 300 cells/lL at some time during the previous year. Study-related blood eosinophil counts were carried out by a central laboratory. The original protocols were approved by local or study research ethics committees and conducted in accordance with good clinical practice guidelines and the Declaration of Helsinki.
Treatment
Patients in MENSA were randomly assigned to mepolizumab, administered as either a 75-mg intravenous (IV) dose or a 100-mg subcutaneous (SC) dose, or matched placebo for 32 weeks [3] . Patients in MUSCA were randomly assigned to mepolizumab 100 mg SC dose, or matched placebo for 24 weeks [4] . The current analysis was restricted to the 100-mg SC dose.
Lung Function
Peak flow was measured using an electronic peak flow meter ASMA-1 (Vitalograph Ltd., UK), which transmitted the peak flow value to the electronic diary (eDiary, PHT Corporation, Boston MA). The data was downloaded from the eDiary device to a centralized server at each visit.
In this post hoc analysis, daily data on AM PEF were summarized into weekly averages to assess a weekly change from baseline AM PEF analysis in the first 4 weeks of treatment and 4-weekly averages to assess a 4-weekly change from baseline in AM PEF analysis for the entire duration of the study. Analyses were performed overall and by stratifying patients into the following baseline blood eosinophil thresholds: C 150 cells/lL, C 300 cells/lL, and C 500 cells/ lL. Baseline blood eosinophil ranges (\ 150 cells/lL, 150 cells/lL to \ 300 cells/lL, and 300 cells/lL to \ 500 cells/lL) were also assessed.
Other Assessments
Annualized rate of exacerbations, SGRQ score, ACQ-5 score, pre-and post-bronchodilator FEV 1 , and safety assessments including immunogenicity, adverse events, and serious adverse events were also evaluated. The results of these assessments have been reported elsewhere [3, 4] .
Statistical Analysis
This post hoc analysis was based on the modified intent-to-treat (mITT) population for MENSA and MUSCA, including all randomized patients who received at least one dose of study medication.
Daily AM PEF data were summarized into weekly and four-weekly averages for each patient. Weekly AM PEF values for the first week of each study and four-weekly AM PEF values for the duration of each study were analyzed using a mixed model repeated measures model in each study separately. The model included covariates of treatment group, baseline AM PEF, region, age, sex, smoking history, atopy, baseline maintenance oral corticosteroid (OCS) use, exacerbations in the year prior to study start (categorized as 2, 3, C 4, included as an ordinal variable), visit, and interaction terms for visit by treatment and visit by baseline AM PEF. This analysis was carried out using absolute AM PEF values as well as log-transformed values to obtain absolute and relative change from baseline estimates, respectively. Adjusted means and treatment effect estimates were generated for each study visit separately and for all study visits combined by applying equal weighting for each visit. Difference from placebo estimates from individual studies were then combined using a fixed-effect meta-analysis using inversevariance weighting. A stratified analysis was performed to obtain estimates within subgroups. All analyses were performed using SAS version 9 (SAS Institute, Cary, NC).
Compliance with Ethics Guidelines
The studies were conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice (GCP), and the applicable country-specific regulatory requirements.
RESULTS
The ITT population included 468 patients from both MENSA and MUSCA, i.e., a total of 936 patients. Demographic characteristics were relatively similar in both placebo and mepolizumab groups (Table 1) .
AM PEF Individual Studies
MENSA Study
Baseline AM PEF was comparable between the mepolizumab and placebo group (295 and 269 L/min), respectively. Early and significant increases from baseline (weeks 1 to 4) were noted in mean (SE) AM PEF in the mepolizumab group, 15 (2.7) L/min compared to -2 (2.8) L/ min in the placebo group (p \ 0.001) (Fig. 1a) . Improvement in AM PEF continued during weeks 5 to 8 in the mepolizumab group, 23 (3.8) L/min) compared to 0 (3.9) L/min in the placebo group (p \ 0.001). At weeks 9 to 12, the mepolizumab group achieved 29 (4.4) L/min increase compared to -1 (4.4) L/min in the placebo group (p \ 0.001). Improvements were sustained during weeks 13-20; at weeks 21-24 the mepolizumab group showed 30 (4.3) L/min improvement compared to 4 (4.4) L/min in the placebo group (p \ 0.001). At the end of the study period (weeks 29-32) there was an improvement in the mepolizumab group of 29 (4.6) L/min compared to 1 (4.7) L/min in the placebo group, p \ 0.001, with a mean change difference from placebo of 28 (95% CI, 15, 41) L/min (Fig. 1a) .
MUSCA Study
Baseline AM PEF was comparable between the mepolizumab and placebo group (312 and 294 L/min), respectively. Also in the MUSCA study early and significant increases from baseline (weeks 1 to 4) were noted in mean (SE) AM PEF in the mepolizumab group, 17 (2.5) L/min compared to 2 (2.5) L/min in the placebo group (p \ 0.001) (Fig. 1b) . Improvements in AM PEF continued during weeks 5-8 in the mepolizu- (Fig. 1b) .
AM PEF Meta-Analysis
In the meta-analysis of the MENSA and MUSCA studies baseline AM PEF in the mepolizumab and placebo group was 304 and 283 L/min, respectively. Early and significant increases in AM PEF from baseline (weeks 1-4) were noted in the mepolizumab group. A mean change difference from placebo of 8 (95% CI 3, 13) L/ min (p \ 0.001) was seen during the first week ( Fig. 2a) with a steady increase overtime. At the end of week 4, AM PEF mean (SD) increased in the mepolizumab group 18 (2.4) L/min compared to 1 (2.4) L/min in the placebo group (p \ 0.001). Improvement in AM PEF continued during weeks 5 to 8 in the mepolizumab group, 22 (2.6) L/min compared to 1 (2.6) L/min in the placebo group (p \ 0.001). Changes reached a plateau at weeks 9 to 12, the mepolizumab group achieved 25 (2.9) L/min increase compared to 2 (2.9) L/min in the placebo group (p \ 0.001). Improvements were sustained as observed in the individual studies during weeks 13 to 20. At weeks 21 to 24, the mepolizumab (Fig. 2b) . We also present the data as percentage change from baseline. Similarly, changes were seen early during the first 4 weeks following treatment with mepolizumab (6% difference from placebo, p \ 0.001) and continued by week 32 (12% difference from placebo, p \ 0.001), the last 8 weeks correspond to MENSA alone ( Fig. 1-S, supplemental material) .
Changes by Eosinophil Counts
The population was analyzed using four primary thresholds: \ 150 cells/lL, C 150 cells/lL, C 300 cells/lL, and C 500 cells/lL. Significant increases from baseline at the end of the study period were noted in mean (SE) AM PEF in all the mepolizumab groups in the meta-analysis. (Fig. 3) . We also analyzed changes at the end of the observational period by blood eosinophil ranges: 150 to \ 300 cells/lL and 300 to \ 500 cells/lL. This analysis was performed to better understand PEF changes over a range of peripheral eosinophil counts. The 150 to \ 300 cells/lL group treated with mepolizumab improved 12 (4.2) L/min compared to -8 (4.2) L/min in the placebo group, with a mean difference of 19 L/min (95% CI 7, 31), p = 0.002. The 300 to \ 500 cells/lL mepolizumab group (Fig. 3b) .
DISCUSSION
In this analysis mepolizumab demonstrated early and meaningful improvement in lung function as measured by daily AM PEF in patients with severe eosinophilic asthma. The data was consistent across the individual studies, MENSA and MUSCA [3, 4] . Results from this analysis in patients with a baseline blood eosinophil count of at least 150 cells/lL or at least 300 cells/lL in the previous year treated with mepolizumab 100 mg SC had a mean AM PEF difference from placebo of 22 L/min. There was a positive association between the improvement in lung function and increasing baseline blood eosinophil count. This association is consistent with a recent meta-analysis in patients with severe eosinophilic asthma evaluating a range of eosinophil thresholds demonstrating greater improvement in exacerbation reduction for mepolizumab with increasing baseline blood eosinophil counts [13] . These findings warrant further discussion. Early studies with mepolizumab were inconsistent in terms of changes in lung function [1, 2] , while these studies demonstrated clear benefit in exacerbation reduction. This enabled a better understanding of the relationship between eosinophilic inflammation and asthma pathobiology. The mepolizumab target population was refined during the mepolizumab development program with the incorporation of key markers to predict response including blood eosinophil count of at least 150 cells/lL at screening or 300 cells/lL in the past 12 months, at least two exacerbations in the past 12 months, and high dose ICS plus another controller [3, 4] . On the basis of this profile, patients in MENSA and MUSCA who received mepolizumab 100 mg SC had a 98-mL and 120-mL improvement in FEV 1 , respectively. While there is limited published PEF data available with biologics, other anti-IL-5 biologics have shown improvements in lung function measured by changes in FEV 1 [14] [15] [16] .
Recently, Chupp and colleagues reported a post hoc analysis from the SIROCCO and CALIMA studies of benralizumab on changes in AM PEF [17] . The data were derived from patients with a baseline blood eosinophil count of C 300 cells/lL. In SIROCCO, changes over the first week in AM PEF from baseline with benralizumab (Q8W) were 14.05 L/min vs. than that seen with benralizumab, it is important to recognize that these are indirect comparisons and therefore cannot directly inform on comparative effectiveness.
The relationship between inflammation and physiological changes is complex. Mepolizumab alters the growth, proliferation, and migration of eosinophils by blocking IL-5 [18] . Eosinophilia in lung tissue is driven by IL-5 and by the recruitment of eosinophils to the lung via the production of chemokines [18, 19] . In patients with severe asthma, several molecular mechanisms have been identified that might account for reduced steroid responsiveness [20] . We hypothesize that some of these altered molecular mechanisms in patients with severe asthma are circumvented by targeted therapies such as mepolizumab, allowing additional clinical benefits on top of ICS therapy, such as those shown in this report.
Peak flow measurements are important for monitoring asthma. However, most of the current studies in severe asthma evaluating lung function focus on FEV 1 measured by standard spirometry [21] . There are several practical advantages in using PEF [22, 23] . Since the PEF is reached very early in a forced expiratory maneuver, the forced expiratory maneuver can be of brief duration and is therefore relatively easy to perform. PEF can be measured with either a mechanical or an electronic peak flow meter. The use of an electronic peak flow meter offers the capability to store multiple readings over time for future download and review with the date and time stamped [19] . Adherence is likely to be better with self-recording electronic meters than with manual flow meters that require data to be recorded in a daily diary. Accordingly, PEF is suitable for individual testing at home during clinical trials [2] [3] [4] 6] , in the workplace to study occupation-related exposures [24] , and in the outpatient healthcare setting [25] . Overall, the collection of daily PEF offers the ability to capture fluctuations in lung function, including periods during and after an exacerbation. In contrast, FEV 1 measured at the clinic (e.g., every 4 weeks in clinical trials) provides only a cross-sectional view of the patient's status at the time of the visit, which could be influenced by an ongoing exacerbation or its related treatment, particularly in the more severe patients. Long-term PEF monitoring is recommended by treatment guidelines for patients with severe asthma, or those with impaired perception of airflow limitation [26] . A minimal clinically important difference (MCID) in PEF has not been fully established, but in asthma clinical trials a change in AM PEF between 19 and 25 L/min from baseline is considered clinically significant [27, 28] .
CONCLUSION
Asthma treatment guidelines [26] highlight the need to achieve asthma control, maintain normal activity levels and lung function, as well as minimizing the risk of exacerbations with few side effects. These results support improvements in lung function across defined eosinophil thresholds and augment the benefits in other markers of asthma control seen with mepolizumab. A limitation of this post hoc analysis is the retrospective nature of the methodology. In conclusion, these findings highlight the utility of PEF in clinical trials and the fact that eosinophil counts are associated with rapid, consistent, and clinically meaningful changes in lung physiology following treatment with mepolizumab when assessed in concert with disease severity, treatment intensity, and exacerbation history.
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